fialuridine has been researched along with cidofovir anhydrous in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chattopadhyay, D; Fan, X; Harden, EA; Johnson, MP; Keith, KA; Kern, ER; Luo, M; McBrayer, A; Prichard, MN; Qiu, S; Torrence, PF | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Meinert, CL | 1 |
1 review(s) available for fialuridine and cidofovir anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for fialuridine and cidofovir anhydrous
| Article | Year |
|---|---|
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
Topics: Amino Acid Sequence; Antiviral Agents; Herpesviridae; Humans; Kinetics; Molecular Sequence Data; Orthopoxvirus; Phosphorylation; Thymidine Kinase; Vaccinia virus | 2007 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
An open letter to the FDA regarding changes in reporting procedures for drugs and biologics proposed in the wake of the FIAU tragedy.
Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Arabinofuranosyluracil; Cidofovir; Cost-Benefit Analysis; Cytosine; Drug Evaluation; Forms and Records Control; Humans; Organophosphonates; Organophosphorus Compounds; Safety Management; United States; United States Food and Drug Administration | 1996 |